ZVRA on Nasdaq
ZEVRA THERAPEUTICS, INC.
American pharmaceutical preparations company based in Celebration.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Zymeworks, Theravance Biopharma, Inc. or ImmunoGen Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-59.1%Operating margin3
78.2%Net margin3
350.9%Revenue growth, 20253
53.8%Return on equity3
0.40×Debt to equity3
-$2.4MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Miplyffa brought in 99% of the revenue ZEVRA THERAPEUTICS, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Miplyffa | $10.1M | $87.4M |
| Olpruva | $100.0K | $800.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin47¢$77.6M
- Income tax2¢$3.4M
- Profit51¢$83.2M
Out of $106.5M in revenue.3
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue, net | $106.5M | $23.6M |
| Cost of product revenue (excluding $X and $X in intangible asset amortization for the years ended XXX XX, 20XX, and 20XX, respectively, shown separately below) | $16.5M | $7.4M |
| Impairment of intangible assets | $58.7M | $0 |
| Research and development | $12.7M | $42.1M |
| Selling, general and administrative | $77.6M | $54.9M |
| Total operating expenses | $90.4M | $97.0M |
| Loss from operations | -$62.9M | -$87.0M |
| Gain on sale of PRV | $148.3M | $0 |
| Interest expense | -$8.0M | -$7.4M |
| Fair value adjustment related to warrant and CVR liability | $2.2M | $2.1M |
| Fair value adjustment related to investments | $149.0K | -$18.0K |
| Interest and other income, net | $6.9M | $2.2M |
| Total other income (expense) | $149.6M | -$3.1M |
| Income (loss) before income taxes | $86.7M | -$90.1M |
| Income tax expense | -$3.4M | -$15.4M |
| Net income (loss) | $83.2M | -$105.5M |
| Basic (in dollars per share) | $1.40 | -$2.28 |
| Diluted (in dollars per share) | $1.35 | -$2.28 |
| Basic (in shares) | 55.3M shares | 46.3M shares |
| Diluted (in shares) | 57.3M shares | 46.3M shares |
| Intangible asset amortization | $3.9M | $6.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $62.4M | $33.8M | |
| Securities at fair value, current | $128.6M | $35.7M | |
| Accounts and other receivables | $23.3M | $10.5M | |
| Prepaid expenses and other current assets | $7.0M | $4.1M | |
| Inventories, current | $1.7M | $2.0M | |
| Total current assets | $223.0M | $86.0M | |
| Securities at fair value, noncurrent | $47.9M | $6.0M | |
| Inventories, noncurrent | $879.0K | $11.0M | |
| Property and equipment, net | $489.0K | $356.0K | |
| Operating lease right-of-use assets | $1.2M | $657.0K | |
| Goodwill | $4.7M | $4.7M | |
| Intangible assets, net | $6.4M | $69.0M | |
| Other long-term assets | $143.0K | $384.0K | |
| Total assets | $284.7M | $178.1M | |
| Accounts payable and accrued expenses | $11.6M | $25.5M | |
| Current portion of operating lease liabilities | $419.0K | $420.0K | |
| Current portion of discount and rebate liabilities | $12.2M | $5.9M | |
| Current portion of income tax payable | $13.7M | $0 | |
| Other current liabilities | $1.4M | $2.3M | |
| Total current liabilities | $39.3M | $34.1M | |
| Long-term debt | $61.9M | $59.5M | |
| Warrant liability | $9.6M | $17.8M | |
| Income tax payable | $7.0M | $14.4M | |
| Operating lease liabilities, less current portion | $859.0K | $372.0K | |
| Discount and rebate liabilities, less current portion | $9.7M | $7.7M | |
| Other long-term liabilities | $1.7M | $4.6M | |
| Total liabilities | $130.1M | $138.5M | |
| Undesignated preferred stock, $X.X par value, X shares authorized, X shares issued or outstanding as of XXX XX, 20XX, or December 31, 20XX | $0 | $0 | |
| Common stock, $X.X par value, X shares authorized; X shares issued and X shares outstanding as of XXXX XX, 20XX; X shares issued and X shares outstanding as of December 31, 20XX | $6.0K | $5.0K | |
| Additional paid-in capital | $588.5M | $555.3M | |
| Treasury stock, at cost | -$11.0M | -$11.0M | |
| Accumulated deficit | -$422.1M | -$505.3M | |
| Accumulated other comprehensive (loss) income | -$764.0K | $631.0K | |
| Total stockholders' equity | $154.7M | $39.7M | $61.9M |
| Total liabilities and stockholders' equity | $284.7M | $178.1M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Par value, common stock (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | |
| Common stock, shares issued (in shares) | 58.3M shares | 55.2M shares | |
| Common stock, shares outstanding (in shares) | 56.9M shares | 53.7M shares | 41.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $62.4M | $33.8M | |
| Securities at fair value, current | $128.6M | $35.7M | |
| Accounts and other receivables | $23.3M | $10.5M | |
| Prepaid expenses and other current assets | $7.0M | $4.1M | |
| Inventories, current | $1.7M | $2.0M | |
| Total current assets | $223.0M | $86.0M | |
| Securities at fair value, noncurrent | $47.9M | $6.0M | |
| Inventories, noncurrent | $879.0K | $11.0M | |
| Property and equipment, net | $489.0K | $356.0K | |
| Operating lease right-of-use assets | $1.2M | $657.0K | |
| Goodwill | $4.7M | $4.7M | |
| Intangible assets, net | $6.4M | $69.0M | |
| Other long-term assets | $143.0K | $384.0K | |
| Total assets | $284.7M | $178.1M | |
| Accounts payable and accrued expenses | $11.6M | $25.5M | |
| Current portion of operating lease liabilities | $419.0K | $420.0K | |
| Current portion of discount and rebate liabilities | $12.2M | $5.9M | |
| Current portion of income tax payable | $13.7M | $0 | |
| Other current liabilities | $1.4M | $2.3M | |
| Total current liabilities | $39.3M | $34.1M | |
| Long-term debt | $61.9M | $59.5M | |
| Warrant liability | $9.6M | $17.8M | |
| Income tax payable | $7.0M | $14.4M | |
| Operating lease liabilities, less current portion | $859.0K | $372.0K | |
| Discount and rebate liabilities, less current portion | $9.7M | $7.7M | |
| Other long-term liabilities | $1.7M | $4.6M | |
| Total liabilities | $130.1M | $138.5M | |
| Undesignated preferred stock, $X.X par value, X shares authorized, X shares issued or outstanding as of XXX XX, 20XX, or December 31, 20XX | $0 | $0 | |
| Common stock, $X.X par value, X shares authorized; X shares issued and X shares outstanding as of XXXX XX, 20XX; X shares issued and X shares outstanding as of December 31, 20XX | $6.0K | $5.0K | |
| Additional paid-in capital | $588.5M | $555.3M | |
| Treasury stock, at cost | -$11.0M | -$11.0M | |
| Accumulated deficit | -$422.1M | -$505.3M | |
| Accumulated other comprehensive (loss) income | -$764.0K | $631.0K | |
| Total stockholders' equity | $154.7M | $39.7M | $61.9M |
| Total liabilities and stockholders' equity | $284.7M | $178.1M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Par value, common stock (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | |
| Common stock, shares issued (in shares) | 58.3M shares | 55.2M shares | |
| Common stock, shares outstanding (in shares) | 56.9M shares | 53.7M shares | 41.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | $83.2M | -$105.5M |
| Stock-based compensation expense | $12.6M | $14.9M |
| Impairment of intangible assets | $58.7M | $0 |
| Inventory obsolescence charge | $11.7M | $5.7M |
| Income tax expense | $3.4M | $15.4M |
| Depreciation and amortization expense | $4.1M | $6.4M |
| Non-cash interest expense | $2.6M | $2.1M |
| Non-cash lease expense | $602.0K | $552.0K |
| Fair value adjustment related to warrant and CVR liabilities | -$2.2M | -$2.1M |
| Accretion on investments | -$3.1M | -$890.0K |
| Fair value adjustment related to investments | -$149.0K | $18.0K |
| Loss on sublease and disposal of property and equipment | $63.0K | $218.0K |
| Consulting fees paid in common stock | $75.0K | $474.0K |
| Loss on foreign currency exchange rates | $1.5M | $219.0K |
| Gain on sale of PRV | -$148.3M | $0 |
| Accounts and other receivables | -$12.0M | $6.9M |
| Prepaid expenses and other current assets | -$2.9M | -$2.2M |
| Inventories | -$1.3M | -$8.9M |
| Other long-term assets | $451.0K | $0 |
| Accounts payable and accrued expenses | -$15.6M | -$3.6M |
| Discount and rebate liabilities | $6.7M | $431.0K |
| Operating lease liabilities | -$675.0K | -$626.0K |
| Other liabilities | -$1.2M | $835.0K |
| Net cash used in operating activities | -$1.6M | -$69.7M |
| Purchases of property and equipment | -$835.0K | $0 |
| Disposals of property and equipment | $448.0K | $0 |
| Purchases of investments | -$310.0M | -$41.2M |
| Maturities of investments | $178.5M | $25.0M |
| Proceeds from sale of PRV | $150.0M | $0 |
| Payment of royalty to XOMA | $0 | -$6.0M |
| Net cash provided by (used in) investing activities | $18.1M | -$22.2M |
| Proceeds from issuance of debt, net of lender fees | $0 | $59.0M |
| Repayment of debt | $0 | -$42.7M |
| Proceeds from insurance financing arrangements | $0 | $1.1M |
| Proceeds from Employee Stock Purchase Plan | $615.0K | $1.1M |
| Proceeds from issuance of stock | $0 | $64.5M |
| Proceeds from issuance of common stock for options exercised | $3.2M | $1.7M |
| Proceeds from issuance of common stock for warrants exercised | $8.6M | $0 |
| Payments of principal on insurance financing arrangements | -$372.0K | -$431.0K |
| Payment of deferred financing costs | $0 | -$2.1M |
| Net cash provided by financing activities | $12.1M | $82.1M |
| Effect of exchange rate changes on cash and cash equivalents | $28.0K | $454.0K |
| Net increase (decrease) in cash and cash equivalents | $28.6M | -$9.3M |
| Cash paid for interest | $5.3M | $5.3M |
| Right-of-use assets obtained in exchange for lease liabilities | $1.1M | $419.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led ZEVRA THERAPEUTICS, INC., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
20202025
- Chief executive officerRichard W. Pascoe Jan 11, 2023 to Mar 13, 202311
- Chief executive officerNeil F. McFarlane Oct 10, 2023 to now12
- Chief executive officerTravis C. Mickle Apr 15, 2015 to May 25, 202213
- ChairRichard W. Pascoe Nov 10, 2021 to May 18, 202214
- PresidentNeil F. McFarlane Oct 10, 2023 to now12
- PresidentTravis C. Mickle Apr 15, 2015 to May 25, 202213
- Chief financial officerJustin A. Renz Mar 19, 2026 to now15
- Chief financial officerGordon K. Johnson Apr 15, 2015 to May 29, 201516
- Chief financial officerR. Laduane Clifton Jun 26, 2015 to Feb 14, 202517
- Chief operating officerGordon K. Johnson Apr 15, 2015 to May 29, 201516
Board members and other officers (25)
- Chief Medical OfficerAdrian W. Quartel Mar 27, 2025 to now18
- CCO & EVP, Bus. DevelopmentJoshua Schafer Jan 10, 2023 to now19
- VP, Corporate ControllerTimothy J. Sangiovanni Feb 16, 2017 to now20
- EVP, Govt and Public RelationsDaniel L. Cohen Apr 15, 2016 to May 17, 201821
- VP Operations & Prod DevChristal M. M. Mickle Apr 15, 2015 to Feb 2, 202422
- VP Fin & Corp ControllerR. Laduane Clifton Apr 15, 2015 to Apr 17, 201523
- Exec VP R&DSven Guenther Apr 15, 2015 to Feb 2, 202424
- Chief Commercial OfficerTracy M. Woody Apr 15, 2015 to Feb 16, 201625
- Chief Business OfficerGordon K. Johnson Jun 26, 2015 to Jan 2, 202026
- Board memberAlicia Secor Dec 9, 2025 to now27
- Board memberAlvin Shih Feb 2, 2024 to now28
- Board memberCorey Michael Watton May 8, 2023 to now29
- Board memberJohn B. Bode May 8, 2023 to now30
- Board memberWendy L. Dixon May 8, 2023 to now31
- Board memberDouglas W. Calder May 11, 2023 to now32
- Board memberNeil F. McFarlane Oct 10, 2023 to now12
- Board memberChristopher Posner Nov 30, 2022 to Nov 30, 202233
- Board memberTamara A. Seymour Aug 18, 2021 to now34
- Board memberDanny L. Thompson Apr 15, 2015 to Jul 2, 201935
- Board memberDavid S. Tierney Apr 15, 2015 to Mar 13, 202336
- Board memberJoseph Saluri Apr 15, 2015 to May 8, 202337
- Board memberMatthew R. Plooster Apr 15, 2015 to May 8, 202338
- Board memberRichard W. Pascoe Apr 15, 2015 to Mar 13, 202339
- Board memberTravis C. Mickle Apr 15, 2015 to May 25, 202213
- General counselRahsaan Thompson Jun 25, 2024 to now40
Former names
Timeline
Filings
363 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 75 major events, 140 insider forms, 21 large holders, 107 other. The latest 20:
- Oct 13, 2026144 EDGAR
- Oct 13, 20264 EDGAR
- Aug 17, 20264 EDGAR
- Aug 14, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 20264 EDGAR
- Aug 6, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 31, 2026SCHEDULE 13G EDGAR
- Jul 8, 2026144 EDGAR
- Jun 23, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 5, 20268-K EDGAR
- May 29, 20264 EDGAR
The 363 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 21 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Aug 6, 2026SCHEDULE 13G/A
- Jul 31, 2026SCHEDULE 13G
- May 6, 2026SCHEDULE 13G
- Mar 27, 2026SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
- Nov 13, 2025SCHEDULE 13G/A
- Feb 14, 2025SCHEDULE 13G/A
- Feb 12, 2025SCHEDULE 13G
- Feb 5, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 5,108,871 | $73.3M | 0.0% | +652,395 |
| Fmr LLC | 4,915,717 | $70.5M | 0.0% | +1,703,840 |
| Woodline Partners LP | 4,785,771 | $68.6M | 0.2% | +1,334,828 |
| Nantahala Capital Management, LLC | 3,594,952 | $51.6M | 1.6% | +1,073,016 |
| Vanguard Capital Management LLC | 2,638,910 | $37.8M | 0.0% | +169,582 |
| State Street Corp | 1,681,999 | $24.1M | 0.0% | +120,430 |
| Geode Capital Management, LLC | 1,540,936 | $22.1M | 0.0% | +169,079 |
| D. E. Shaw & Co., Inc. | 1,306,949 | $18.7M | 0.0% | +460,492 |
| Qube Research & Technologies Ltd | 1,241,343 | $17.8M | 0.0% | +399,024 |
| Morgan Stanley | 1,203,875 | $17.3M | 0.0% | +11,613 |
| Legal & General Group Plc | 1,201,668 | $17.2M | 0.0% | +38,578 |
| Dimensional Fund Advisors LP | 958,836 | $13.7M | 0.0% | +404,034 |
| Royce & Associates LP | 882,658 | $12.7M | 0.1% | −106,016 |
| 683 Capital Management, LLC | 855,000 | $12.3M | 1.2% | −120,000 |
| Kingdon Capital Management, L.l.c. | 775,000 | $11.1M | 1.5% | No change |
| Retirement Planning Co of New England, Inc. | 634,410 | $9.1M | 3.3% | −16,738 |
| Jupiter Topco LLC | 613,403 | $8.8M | 0.0% | New |
| Arrowstreet Capital, Limited Partnership | 597,162 | $8.6M | 0.0% | New |
| Goldman Sachs Group Inc | 545,551 | $7.8M | 0.0% | −197,573 |
| Vanguard Portfolio Management LLC | 541,109 | $7.8M | 0.0% | +74,806 |
| Northern Trust Corp | 486,498 | $7.0M | 0.0% | +49,548 |
| Swedbank AB | 439,410 | $6.3M | 0.0% | New |
| Schroder Investment Management Group | 439,328 | $6.2M | 0.0% | −66,705 |
| Tudor Investment Corp Et Al | 415,058 | $6.0M | 0.0% | −28,051 |
| Stratos Wealth Partners, LTD. | 408,000 | $5.9M | 0.1% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARRichard W. Pascoe, Chair
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24SEC EDGARSven Guenther, Exec VP R&D
- 25
- 26
- 27SEC EDGARAlicia Secor, Board member
- 28SEC EDGARAlvin Shih, Board member
- 29SEC EDGARCorey Michael Watton, Board member
- 30SEC EDGARJohn B. Bode, Board member
- 31SEC EDGARWendy L. Dixon, Board member
- 32SEC EDGARDouglas W. Calder, Board member
- 33SEC EDGARChristopher Posner, Board member
- 34SEC EDGARTamara A. Seymour, Board member
- 35SEC EDGARDanny L. Thompson, Board member
- 36SEC EDGARDavid S. Tierney, Board member
- 37SEC EDGARJoseph Saluri, Board member
- 38SEC EDGARMatthew R. Plooster, Board member
- 39SEC EDGARRichard W. Pascoe, Board member
- 40SEC EDGARRahsaan Thompson, General counsel
- 41